These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 15931139)

  • 1. Acellular pertussis vaccines for adolescents.
    Pichichero ME; Casey JR
    Pediatr Infect Dis J; 2005 Jun; 24(6 Suppl):S117-26. PubMed ID: 15931139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acellular pertussis vaccine safety and efficacy in children, adolescents and adults.
    Casey JR; Pichichero ME
    Drugs; 2005; 65(10):1367-89. PubMed ID: 15977969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acellular pertussis vaccine for adolescents.
    de Carvalho AP; Pereira EM
    J Pediatr (Rio J); 2006 Jul; 82(3 Suppl):S15-24. PubMed ID: 16786100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model.
    Kwon HJ; Han SB; Kim BR; Kang KR; Huh DH; Choi GS; Ahn DH; Kang JH
    BMC Infect Dis; 2017 Apr; 17(1):247. PubMed ID: 28376777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial.
    Sricharoenchai S; Sirivichayakul C; Chokephaibulkit K; Pitisuttithum P; Dhitavat J; Pitisuthitham A; Phongsamart W; Boonnak K; Lapphra K; Sabmee Y; Wittawatmongkol O; Chinwangso P; Poredi IK; Petre J; Thai PH; Viviani S
    Lancet Infect Dis; 2018 Jan; 18(1):58-67. PubMed ID: 29066131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Broder KR; Cortese MM; Iskander JK; Kretsinger K; Slade BA; Brown KH; Mijalski CM; Tiwari T; Weston EJ; Cohn AC; Srivastava PU; Moran JS; Schwartz B; Murphy TV;
    MMWR Recomm Rep; 2006 Mar; 55(RR-3):1-34. PubMed ID: 16557217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vaccinations to healthy adults.
    Thierry-Carstensen B; Jordan K; Uhlving HH; Dalby T; Sørensen C; Jensen AM; Heilmann C
    Vaccine; 2012 Aug; 30(37):5464-71. PubMed ID: 22776216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
    America Academy of Pediatrics Commitee on Infectious Diseases
    Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adult formulation of a five component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults.
    Halperin SA; Smith B; Russell M; Scheifele D; Mills E; Hasselback P; Pim C; Meekison W; Parker R; Lavigne P; Barreto L
    Pediatr Infect Dis J; 2000 Apr; 19(4):276-83. PubMed ID: 10783014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced-antigen, combined diphtheria-tetanus-acellular pertussis vaccine, adsorbed (Boostrix) US formulation): use as a single-dose booster immunization in adolescents aged 10-18 years.
    Frampton JE; Keam SJ
    Paediatr Drugs; 2006; 8(3):189-95; discussion 196. PubMed ID: 16774298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
    Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A;
    Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A modified vaccine reduces the rate of large injection site reactions to the preschool booster dose of diphtheria-tetanus-acellular pertussis vaccine: results of a randomized, controlled trial.
    Scheifele DW; Halperin SA; Ochnio JJ; Ferguson AC; Skowronski DM
    Pediatr Infect Dis J; 2005 Dec; 24(12):1059-66. PubMed ID: 16371866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the reactogenicity of Tdap vaccine administered during pregnancy and antibodies to Bordetella pertussis antigens in maternal and cord sera of Thai women.
    Wanlapakorn N; Maertens K; Chaithongwongwatthana S; Srimuan D; Suratannon N; Vongpunsawad S; Tran TMP; Hens N; Van Damme P; Locht C; Poovorawan Y; Leuridan E
    Vaccine; 2018 Mar; 36(11):1453-1459. PubMed ID: 29426663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study.
    Kovac M; Kostanyan L; Mesaros N; Kuriyakose S; Varman M
    Hum Vaccin Immunother; 2018; 14(8):1977-1986. PubMed ID: 29630439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents.
    Pichichero ME; Blatter MM; Kennedy WA; Hedrick J; Descamps D; Friedland LR
    Pediatrics; 2006 Apr; 117(4):1084-93. PubMed ID: 16585302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults.
    Halperin SA; Smith B; Russell M; Hasselback P; Guasparini R; Skowronski D; Meekison W; Parker R; Lavigne P; Barreto L
    Vaccine; 2000 Jan; 18(14):1312-9. PubMed ID: 10618527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults.
    Sirivichayakul C; Chanthavanich P; Limkittikul K; Siegrist CA; Wijagkanalan W; Chinwangso P; Petre J; Hong Thai P; Chauhan M; Viviani S
    Hum Vaccin Immunother; 2017 Jan; 13(1):136-143. PubMed ID: 27686283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults.
    Leroux-Roels G; Lattanzi M; Solis CD; Contorni M; Costantini M; Moraschini L; Bardelli M; Bertholet S; Borgogni E; Buricchi F; Cantisani R; Faenzi E; Finco O; Leuzzi R; Pizza M; Rosa D; Schiavetti F; Seubert A; Spensieri F; Volpini G; Zedda L; Giudice GD; Galgani I
    Hum Vaccin Immunother; 2018 Jan; 14(1):45-58. PubMed ID: 29172945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic considerations for pertussis booster vaccination in adolescents.
    Hay JW; Ward JI
    Pediatr Infect Dis J; 2005 Jun; 24(6 Suppl):S127-33. PubMed ID: 15931140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tdap5 vaccine (Covaxis): a review of its use as a single-booster immunization for the prevention of tetanus, diphtheria, and pertussis in children (aged 4 years), adolescents, and adults.
    Scott LJ
    BioDrugs; 2010 Dec; 24(6):387-406. PubMed ID: 21043546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.